Natural source d-α-tocopheryl acetate

PreclinicalSmall molecule

Natural source d-α-tocopheryl acetate is one of 8 small molecule programs targeting Allergic Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

Allergic AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Allergic Asthma

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Preclinical

1 2

JYB1904

JJemincare

Phase 2

1 3

FB825

OOneness Biotech Co., Ltd.

Phase 2

1 4

Singulair

OOrganon and Co

Preclinical

—5

Kenalog

BBausch Health Americas, Inc.

Preclinical

—6

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

—7

Natural source d-α-tocopheryl acetate

VVanderbilt University

Preclinical

1 8

Salbutamol /ml

MMcMaster University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Asthma1 trial

Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics

Completed·VVanderbilt University·N/A·NCT00581048·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Natural source d-α-tocopheryl acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Natural source d-α-tocopheryl acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Natural source d-α-tocopheryl acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University

Natural source d-α-tocopheryl acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Asthma1 trial

References

Drug Info

Quick Facts

Related News